61 results about "Cerebral arterial spasm" patented technology

A method, apparatus, and surgical technique for the modulation of autonomic function, for the purpose of treating any of several conditions and diseases, including obesity, metabolic disorders, endocrine disorders, diabetes, respiratory disease, asthma, inflammatory disease, immunological disease, infection, cancer, cardiac disease, cardiovascular disease, cerebrovascular disease, stroke, vasospasm, vascular disease, psychiatric disease, depression, affective disorders, anxiety disorders, and other conditions. This includes neural and tissue modulators, including implanted devices, used to modulate efferent and afferent autonomic neurons to influence or control autonomic or other neural function, including modulation of sympathetic and parasympathetic nervous system components as well as their combination.

The present invention relates to a method of prevention and treatment of narrowing of cerebral blood vessels after subarachnoid hemorrhage, and in particular, to a method of applying electrical energy through electrical stimulation electrodes particularly positioned in the cervical region of a patient to affect the sympathetic tone of the blood vessels supplying the brain.

The present invention relates to devices and systems that alter intracranial compliance, cerebral blood flow and / or intracranial pressure pulsatility / waveform by oscillating the contraction and expansion of a compressible composition within the cranial or spinal cavities such that they increase intracranial capacity. The contraction and expansion of the compressible composition in the oscillating compliance devices can be due to an individual's intracranial pressure, the result of the expansion and compression of a reservoir which is mediated by the contractility of the heart or driven by a pump gaited to a biorhythm. The invention also relates to methods for protecting an individual's brain from abnormal arterial pulsations and for altering an individual's cerebral blood flow using the devices and systems of the invention. The oscillating compliance devices can be used to treat several diseases and / or conditions characterized by altered / abnormal intracranial compliance, cerebral blood flow and / or intracranial pressure pulsatility / waveform, including hydrocephalus, stroke, dementia and migraine headaches, vasospasms, congestive heart failure, cardiopulmonary bypass or carotid endarterectomy.

Novel systems enable PTNA rapid exchange (RX) types of systems for ICAD, support balloon test occlusion, treatment of vasospasm after sub-arachnoid hemorrhage (SAH) and facilitate aneurysm neck remodeling during coiling embolization. The systems disclosed include an embodiment having a catheter comprising a RX port for providing catheter support within and above the carotid siphon and distal vertebral arteries, a conformable, semi-compliant balloon manipulable to gain forward progress through intracranial vessels substantially narrowed by plaque in combination with at least a guidewire, and a tip disposed at a distal end of the catheter.

The invention relates to methods and products for treatment of hypertension, high blood pressure and vasospasm. Specifically, TRPC3 channel inhibitors and related compositions and kits are described.

A device and method for treatment of intracranial vasospasm is provided. The device is a microcatheter having a steeply tapered end and is thicker walled, and in a preferred embodiment is braided to provide greater pushability. In order to achieve a thicker walled catheter, in one embodiment, the inner lumen diameter can be reduced, leaving the outer diameter the same while in another embodiment the catheter is larger in outer diameter. In one embodiment, the microcatheter is coated with performance enhancing lubricant, such as a hydrophilic coating. Further, the microcatheter can also be coated with drugs and serve as a drug delivery device, drugs being embedded into vessel intima. In the use of the method of treatment, the device is fed into the smaller arterial vessels in the brain simultaneously dilating arteries of various caliber along the path of the catheter to relieve vasospasm; pharmacological agents can then be delivered by the microcatheter to further effect treatment.

The present invention relates to devices and systems that alter intracranial compliance, cerebral blood flow and / or intracranial pressure pulsatility / waveform by oscillating the contraction and expansion of a compressible composition within the cranial or spinal cavities such that they increase intracranial capacity. The contraction and expansion of the compressible composition in the oscillating compliance devices can be due to an individual's intracranial pressure, the result of the expansion and compression of a reservoir which is mediated by the contractility of the heart or driven by a pump gaited to a biorhythm. The invention also relates to methods for protecting an individual's brain from abnormal arterial pulsations and for altering an individual's cerebral blood flow using the devices and systems of the invention. The oscillating compliance devices can be used to treat several diseases and / or conditions characterized by altered / abnormal intracranial compliance, cerebral blood flow and / or intracranial pressure pulsatility / waveform, including hydrocephalus, stroke, dementia and migraine headaches, vasospasms, congestive heart failure, cardiopulmonary bypass or carotid endarterectomy.

An object of the present invention is to provide an agent for treating or preventing vasospasm. An object of the present invention is to provide an agent for treating or preventing cerebral vasospasm as well as arterial vasospasm. Further, an object of the present invention is to provide an agent for treating or preventing cerebral ischemia and cerebral infarction.The above problems are solved by an agent for treating and preventing vasospasm, cerebral ischemia, or cerebral infarction, comprising trehalose as the active ingredient. It is possible, by using such a trehalose-comprising agent, to suppress phenomena such as contraction of blood vessel and thickening of tunica intima and tunica media and to prevent or treat vasospasm and vasospasm-dependent diseases.

The present invention provides novel polypeptides comprising heat shock protein 20 (HSP20)-derived polypeptides to treat or inhibit smooth muscle vasospasm, as well to treat and inhibit smooth muscle cell proliferation and migration.

The present invention relates to the treatment and prevention of vasospasm. The present invention provides a system for treating a cerebral vasospasm in a human utilizing a pharmaceutical composition and administrating a therapeutically effective amount of the pharmaceutical composition to a predetermined location in close proximity to a cerebral artery within a subarachnoid space, wherein the pharmaceutical composition produces a localized pharmacologic effect thereby treating the cerebral vasospasm.

Cerebral Catheter devices and methods for use are provided. The catheter devices provided may include an anti-thrombotic agent coating on the exterior surface. The catheter devices may include unique tip configurations to allow improved fluid delivery capabilities. Further, the catheter devices may also or alternatively include one or more sensor devices in communication with a controller that allow automatically adjusting the delivery of a therapeutic fluid, for example a vasodilator, in response to the condition sensed by the catheter device, such as increased pressure. Moreover, the catheter devices may also be used in conjunction with blood flow transducers to detect and timely prevent and treatment vasospasms or other conditions. Methods for preventing and treatment vasospasm, neoplasm, or other pathological conditions while prolonged using the catheter device are also provided.

Methods and compositions for preventing or reducing vascular smooth muscle contraction are provided. Exemplary compositions comprise an MLCK inhibitor, for example wortmannin, in an amount effective to prevent or reduce vascular smooth muscle vasospams by about 90% for at least about 20 minutes. Methods for identifying other modulators of MLCK are also provided.

A delivery system for sustained release of a calcium-channel blocking agent is adapted for introduction in the cerebrospinal fluid of a subject. The delivery system comprises a solid dispersion product of a calcium-channel blocking agent in a mixture of a (i) first poly(lactide-co-glycolide) having a molecular weight distribution centered around a first number average molecular weight Mn1 and a (ii) second poly(lactide-co-glycolide) having a molecular weight distribution centered around a second number average molecular weight Mn2, wherein Mn1 is in the range of from 2000 to 3000 g / mol and the ratio of Mn1 / Mn2 is from 1.8 to 3.5. The delivery system is deposited in the vicinity of or adjacent to a blood vessel showing vasospasm or suspected of developing vasospasm.

Novel polymorphic forms of bosentan and processes for their preparation are disclosed. Further, pharmaceutical compositions comprising said polymorphic forms and the use of said compositions in the treatment of patients suffering from endothelin receptor mediated disorders, for example, cardiovascular disorders such as hypertension, pulmonary hypertension, ischemia, vasospasm and angina pectoris are disclosed.

Compositions and methods for the treatment of vasospasm are provided comprising applying an amount of a semi-solid vasoactive prostaglandin composition to the affected tissue. Also provided are methods of improving microcirculation in a replanted body part.

The present invention relates to amino butanetriol aescin and its isomer for relieving swelling, diminishing inflammation and improving blood circulation. The amino butanetriol aescin is prepared with amino butanetriol and aescin, and has the structural formula as shown. The amino butanetriol aescin has high water solubility, lowered possibility of resulting in vasospasm and raised administrating safety.

The invention provides a method for establishing a coronary artery microvascular spasm pig-model, and belongs to the technical field of medical models. The method comprises that after bilateral femoral arteries of a test pig are free, distal ends of the femoral arteries are ligatured by wires, a left-side sheathing canal is fed into a pigtail catheter, blood flow dynamics indexes are determined, in a right-side sheathing canal, a coronary artery radiography process is carried out so that the middle of an anterior descending branch is displayed, and a neuropeptide Y is injected into the coronary artery so that the coronary artery microvascular spasm pig-model is obtained. The coronary artery microvascular spasm pig-model has good singularity, well fits to the clinical disease fact, satisfies clinical psychological stress characteristics, can be operated simply, is scientific and reasonable, has short modeling time, small damage and low animal mortality, realizes coronary artery microvascular evaluation on the carrier, realizes qualitative and quantitative evaluation of microvascular spasm state and degree, realizes real-time observation, provides a novel research means for basic clinical research and is suitable for popularization application.

A device and method for treatment of intracranial vasospasm is provided. The device is a microcatheter having a steeply tapered end and is thicker walled, and in a preferred embodiment is braided to provide greater pushability. In order to achieve a thicker walled catheter, in one embodiment, the inner lumen diameter can be reduced, leaving the outer diameter the same while in another embodiment the catheter is larger in outer diameter. In one embodiment, the microcatheter is coated with performance enhancing lubricant, such as a hydrophilic coating. Further, the microcatheter can also be coated with drugs and serve as a drug delivery device, drugs being embedded into vessel intima. In the use of the method of treatment, the device is fed into the smaller arterial vessels in the brain simultaneously dilating arteries of various caliber along the path of the catheter to relieve vasospasm; pharmacological agents can then be delivered by the microcatheter to further effect treatment.

Novel polymorphic forms of bosentan and processes for their preparation are disclosed. Further, pharmaceutical compositions comprising said polymorphic forms and the use of said compositions in the treatment of patients suffering from endothelin receptor mediated disorders, for example, cardiovascular disorders such as hypertension, pulmonary hypertension, ischemia, vasospasm and angina pectoris are disclosed.

The invention discloses application of anisodine hydrobromide in preparing medicines for preventing or treating depression, in order to develop a medicine for effectively preventing or treating depression. Anisodine has the chemical formula of C17H21NO5 and a relative molecular weight of 319.35, is a pyrethroid type alkaloid, is present in belladonna plants and is a choline receptor blocking agent isolated firstly in China. The hydrobromide of the anisodine is mainly used clinically, and can be used for treating vascular headache, retinal vasospasm, central retinopathy, ischemic optic neuropathy, acute paralysis, paralysis agitans, bronchial asthma, kinesia, organic phosphorus pesticide poisoning and the like. However, literatures reporting treatment of depression are not available. In the invention, experiments show that anisodine hydrobromide plays a role in treating depression, and has a very good therapeutic effect in depression symptoms of interest blank, pleasant sensation disappearance, reduced exiting degree, reduced increment of body weight and the like.

This invention relates to methods and systems for providing a prognosis to a subject on developing vasospasm as a results of hemorrhagic event, and compounds and compositions for treatment thereof. Specifically, the invention relates to the use of haptoglobin genotyping in the prognosis of the development of vasospasm following SAH, and antioxidants such as glutathione peroxidase mimetics for treatment.

A therapeutic agent for subarachnoid hemorrhage or a drug for improving prognosis of subarachnoid hemorrhage, comprising a compound having a PAR1 inhibitory effect, its pharmaceutically acceptable salt or a hydrate thereof.

A method and solution for perioperatively inhibiting a variety of pain, inflammation, spasm and restenosis processes resulting from cardiovascular or general vascular therapeutic and diagnostic procedures. The solution preferably includes multiple pain and inflammation inhibitory agents and spasm inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. Specific preferred embodiments of the solution of the present invention for use in cardiovascular and general vascular procedures also include anti-restenosis agents. The solution is introduced luminally to continuously irrigate an arterial site during an operative / interventional or diagnostic procedure for preemptive inhibition of pain and inflammation, vascular and non-vascular smooth muscle spasm, and restenosis while avoiding undesirable side effects associated with oral, intramuscular, subcutaneous or intravenous application of larger doses of the agents. One preferred solution to inhibit pain, inflammation, vasospasm and restenosis includes a serotonin2 antagonist, a cyclooxygenase inhibitor, an endothelin antagonist, an ATP-sensitive K<+> channel antagonist, a Ca<2+> channel antagonist, a nitric oxide donor, an anti-thrombin agent, a glycoprotein IIb / IIIa receptor blocker, a PKC inhibitor and a protein tyrosine kinase inhibitor.

The invention discloses a Chinese traditional medicine composite for treating migraine, which belongs to the Chinese traditional medicine field. The Chinese traditional medicine composite is prepared by 30 grams of hemlock parsley, 30 grams of coix seed, 15 grams of kudzu root, 15 grams of parsnip, 15 grams of red paeonia, 15 grams of viter rotundifolia, 10 grams of rhizoma gastrodiae, 10 grams of larva of silkworm, 5 grams of scorpio, 3 centipede, 3 grams of brassica alba boiss, and 3 grams of as arum. Firstly, the above materials are soaked in water for 2 hours, then are boiled for 30 minutes, the medicine liquid is poured out; the materials are boiled for 30 minutes again, the medicine is poured out; the twice medicine liquid are mixed together and cooled completely, and then are respectively taken half an hour before the breakfast and two hours after the supper. Ten days of consecutive taking is a period of treatment. The Chinese traditional medicine composite can ease vasospasm, reduce blood vessel resistance, regulate blood viscosity, meliorate and prevent migraine caused by various causes of disease, and can help the headache sufferer be free from western medicine without recrudescence after cure.

The invention relates to screening methods and test systems for the in vitro diagnosis and detection of an increased risk of vasospasm in a patient. In addition, the invention describes the use of GAPDH and / or Hsc70 to diagnose an increased risk of vasospasm. Also described is a method for identifying a pharmaceutically active substance for the prevention and / or treatment of cerebral vasospasm and a method for screening a substance library to identify a pharmaceutically active substance for the prevention and / or treatment of cerebral vasospasm. Pharmaceutically active substances and combination preparations are also disclosed.

The invention discloses application of sorafenib shown in a formula (I) to the preparation of a medicinal composition for treating cerebral vasospasm (CVS) after subarachnoid hemorrhage (SAH). Animal experiments prove that BAY 43-9006 has the effect of obviously inhibiting the CVS after the SAH, and can be used for improving the CVS after the SAH.

The invention is directed to nonpeptide substituted spiroheterobenzazepine of Formula I, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, hyponatremia, renal vasospasm, renal insufficiency, renal failure, diabetic nephropathy, cerebral edema, cerebral ischemia, stroke, thrombosis, or water retention are also disclosed.

The invention provides a nanometer fiber membrane. The nanometer fiber membrane comprises a degradable membrane carrier and a vasospasm resisting drug which is doped in the degradable membrane carrier, wherein the degradable membrane carrier is made of degradable materials. The nanometer fiber membrane which is provided by the invention comprises the vasospasm resisting drug, the vasospasm resisting drug which is doped in the degradable membrane carrier can be well attached and matched with a vessel as a sustained release drug of the implantable vasospasm resisting drug to prevent and treat vasospasm, the utilizing rate of the drug required for a part is high, and the frequent intramuscular administration of the vasospasm resisting drug is not needed. The nanometer fiber membrane is degradable, and the release speed of the vasospasm resisting drug is controlled through the control of the degrading speed of the degradable membrane carrier. Besides, the biodegradability of the nanometer fiber membrane is great, no fiber materials are left in the body after degrading, and no cell toxicity, inflammation reaction or tissue proliferation occurs. The nanometer fiber membrane has great flexibility and tensile performance, can resist extrusion and stretching in the vascular repair process and is suitable for supporting cell growth or drug delivery.

The invention discloses a portable device for recognizing vasospasm. The portable device comprises a mobile terminal, a cloud server and an eye collection mechanism, wherein the mobile terminal comprises a microprocessor and an information entry unit, a body monitoring unit, a collection reminding unit and a mobile communication unit which are connected with the microprocessor; the cloud server comprises a cloud processor and a cloud storage unit and a cloud communication unit which are connected with the cloud processor, the cloud processor is also connected with a picture processing unit, apicture feature extraction unit and a picture comparison unit in sequence, and the cloud communication unit is connected with the mobile communication unit; the eye collection mechanism cooperates with a camera of the mobile terminal. The invention further discloses a use method of the portable device, which can achieve image collection of the posterior segment of the eye and automatic measurementof the diameter of the accompanying fundus vessels based on an internal database of the system, automatically judge the spasticity of peripheral vessels, and achieve the functions of effective collection, storage, management and preliminary screening of vasospasm image information.